In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1-Reference-Cited by-同舟云学术

In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1

Published:2020-10-23 Issue:2 Volume:23 Page:241-249
ISSN:1536-1632
Container-title:Molecular Imaging and Biology
language:en
Short-container-title:Mol Imaging Biol

Author:

Rubins Daniel J^ORCID,Meng Xiangjun,McQuade Paul,Klimas Michael,Getty Krista,Lin Shu-An,Connolly Brett M.,O’Malley Stacey S.,Haley Hyking,Purcell Mona,Gantert Liza,Holahan Marie,Lindgren Joel,Eklund Pär,Ekblad Caroline,Frejd Fredrik Y.,Hostetler Eric D.,González Trotter Dinko E.,Evelhoch Jeffrey L.

Funder

Merck

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11307-020-01544-2.pdf

Reference65 articles.

1. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461

2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB (2012) and others. Safety, activity, and immune correlates of anti–PD-1 antibody in Cancer. N Engl J Med 366(26):2443–2454

3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465